Neurology Main > Neurophysiology Division
ln

Neurophysiology Division
Epilepsy Program
Clinical Trials

Appointments and Referrals

Faculty
- Jacquelyne Cios, MD
- Sheri Cotterman-Hart, MD, PhD
- Charles Hall, MD, PhD
- Meena Khan, MD
- Lucretia Long, MS, RN, CANP
- James McAuley, RPh, PhD
- Jesse Mindel, MD
- Bassel Shneker, MD
Research Staff
- Janet Renner, REEGT
- Stephanie Scarberry, RN

Contact Us

Dr. MooreJ. Layne Moore, MD, MPH
Director, Division of Neurophysiology
Associate Professor of Neurology
Associate Professor of Pharmacy

OSU Appointment: 1993

Background: Dr. Moore grew up in Ada, Ohio where his parents taught at Ohio Northern University. He earned a B.S. from Ohio Northern University with honors in dual majors of Biology and Psychology in 1982. He received his medical training from Wright State University School of Medicine in Dayton, Ohio in 1987 and was elected to Alpha Omega Alpha medical honor society.

His internship in Internal Medicine at West Virginia University Hospitals in Morgantown West Virginia and Residency in Neurology at The University of Cincinnati were completed in 1991.

Doctor Moore completed two Fellowships in Electroencephalography and Epilepsy at the Mayo Clinic in Rochester Minnesota by 1991-1993. He joined the Department of Neurology in 1993.

He completed his Masters Degree in Public Health at The Ohio State University College of Public Health December 2004. He was elected to Phi Kappa Phi honor society during his graduate school.

Board Certification: Neurology 1995, Clinical Neurophysiology 1997, Sleep Medicine 2009

Clinical Interests: Epilepsy, Sleep Medicine, Epidemiology, Women with epilepsy, Investigational drug studies

Research Grants:
Gustavus & Louise Pfeiffer Research Foundation (9/2008-8/2009)
Title: Minimizing the burden of polytherapy antiepileptic drug regimen in patients with intractable epilepsy

Clinical Trials - J. Layne Moore, M.D., M.P.H. - click here to expand or contract list -
Co-investigator, Tiagabine HCL, Protocol M91-605, "Safety and Efficacy of BID and QID dosing with Tiagabine HCL versus Placebo as Adjunctive Treatment for Partial Seizures".
Co-investigator, Tiagabine HCL, Protocol M91-604, "An Open-Label Extension Study of Tiagabine HCL in the Treatment of Patients with Partial Seizures". Mayo Clinic, Rochester, MN.
Co-investigator, Felbamate, Protocol 242, "Compassionate Use of Felbamate in Patients with Epilepsy".
Co-investigator, Topiramate, Protocols YE, YKT, YKP, YLT.
Co-investigator, Topiramate, Protocol YG, "A Double-Blind, Placebo-Controlled, Parallel, Efficacy and Safety Study of Topiramate in Patients with Partial Epilepsy Followed by Topiramate Single Therapy as Accomplished by the Reduction of Concomitant Dilantin (Phenytoin)".
Co-investigator, Felbamate Protocol 255C, "A Multicenter, Open-Label, Long-Term Evaluation of the Safety of Felbamate in Subjects with Epilepsy".
Principal Investigator, Tiagabine HCI, Protocol M93-090, "Monotherapy Multicenter Trial".
Principal Investigator, Tiagabine HCI, Protocol M91-604, "An Open-Label Extension of Tiagabine HCI in the Treatment of Patients with Partial Seizures", The Ohio State University Hospitals, Columbus, Ohio
Principal Investigator, Vigabatrin Protocol VGPR0101, "Efficacy of Rational Polytherapy with Sabril Versus Carbamazepine Monotherapy in the Management of Patients with Non-refractory Complex Partial Seizures".
Principal Investigator, Tiagabine HCI, Protocol M92-825, "Safety and Efficacy of Tiagabine HCI as Adjuctive Treatment".
Principal Investigator, Losigamone, Protocol LSG-1, "A Randomized, Placebo-Controlled Double-Blind Study of the Efficacy and Safety of Losigamone in Patients with Inadequately Controlled Partial Seizures".
Principal Investigator, Ganaxalone, Protocol 1042-0104, "A Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Antiepileptic Activity of Ganaxalone in Patients Undergoing Evaluation to Determine Suitability for Surgical Treatment of Complex Partial Seizures".
Principal Investigator, Pregabalin, Protocol 1008-009/010, "Double-Blind, Placebo-Controlled, Multicenter Study in Patients with Complex Partial Seizures with or without Secondary Generalization".
Principal Investigator, Pregabalin, Protocol 1008-007, "Pregabalin In-Patient Monotherapy Trial: A Double-Blind, Positive-Controlled, Multicenter Study in Patients with Refractory Partial Epilepsy".
Prinicipal Investigator, Pregabalin Open-Label, Follow-On Safety Trial in Patients with Partial Epilepsy. (Protocol 1008-008)
Principal Investigator, Pregabalin Open-Label Add-On Trial: An Open-label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients with Partial Seizures. (1008-010)
Principal Investigator, Pregabalin BID Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients with Partial Seizures. (1008-035)
Principal Investigator, SP667 A Multicenter, Double-blind, Randomized, Placebo-Controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200 mg/day, 400 mg/day, 600 mg/day) as Adjunctive Therapy in Subjects with Partial Seizures with or without Secondary Generalization.
Principal Investigator, SP615 An open-label extension trial to determine tolerability and efficacy of long-term oral SPM 927 as adjunctive therapy in patients with partial seizures
Principal Investigator, SP754 A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of SPM 927 (400 and 600 mg/day) as Adjunctive Therapy in Subjects with Partial Seizures with or without Secondary Generalization
Principal Investigator, SP756 An Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral SPM 927 in Patients with Partial Seizures.
Prinicpal Investigator,LAM40112 Double-blind Randomized Trial of Cognitive Effects of LAMICTAL (lamotrigine) versus Topiramate in Epilepsy
Sub-Investigator, LAM40124 An Assessment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy
Principal Investigator, LAM40117 A MultiCenter Open-Label, Pilot Study of Lamotrigine as Adjunctive Therapy and Monotherapy in Patients with Epilepsy and Comorbid Depressive Symptoms
Principal Investigator, LAM100034: A Multicenter, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures
Principal Investigator, LAM100036: A Multicenter, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures
Principal Investigator, SPD433.401 A Multicenter, Open Label, Phase VI Study to Assess the Tolerability, Safety, and Effectiveness of Switching from Carbamazepine Immediate Release and Liquid Formulations to Carbatrol Extended Release Capsules in Epilepsy Subjects within a Community Based Population
Sub-Investigator, 333369-EPY-2003/2006: A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Refractory Partial Seizures
Sub-Investigator, E2007-A0001-206: A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E20007 Given as Adjunctive Therapy in Patients with Refractory Partial Seizures
Sub-Investigator, IXL-201-14-189: Efficacy and Safety of Talampanel as Adjunctive Therapy in Patients with Partial Seizures: A Phase II Clinical Trial
Sub-Investigator, IXL-201F-14-189: Talampanel Open-Label Adjunctive Therapy: A Follow-On Study to Determine Long-Term Safety and Efficacy in Patients with Partial Seizures
Sub-Investigator, N01191: An open-label, exploratory, multicenter, dose-escalation study examining the efficacy, safety and tolerability of UCB 44212
Sub-Investigator, N01192: An open-label, exploratory, multicenter, dose-escalation study examining the efficacy, safety and tolerability of UCB 44212
Principal Investigator, Neurodevelopment Effects of Antiepileptic Drugs (NEAD) NIH funded multicenter study
Sub-Investigator, N01193: A multicenter, double-blind, randomized, placebo-controlled, 4 parallel groups, dose-ranging trial evaluating the efficacy and safety of brivaracetam used as adjunctive treatment
Principal Investigator, VXR-RET-E22-301: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures
 

Publications: Pubmed.com list of recent publications by J. Layne Moore, M.D., M.P.H.

Appointment Phone: (614) 293-4969
Fax: (614) 293-6111

Address:
395 W. 12th Ave, 7th Floor
Columbus, OH 43210